Belsomra vs Dayvigo: Head-to-Head Efficacy Compared

What These Two Drugs Actually Do

Both suvorexant and lemborexant belong to the dual orexin receptor antagonist class, commonly abbreviated DORA. They block orexin-1 and orexin-2 receptors in the lateral hypothalamus, reducing the brain's wakefulness-promoting signal rather than globally depressing the central nervous system the way benzodiazepines or Z-drugs do. 1

The Orexin System in Brief

Orexin (also called hypocretin) is a neuropeptide that keeps the brain awake. In people with insomnia, orexin signaling remains active when it should quiet down at bedtime. 2 DORAs competitively antagonize both receptor subtypes, which distinguishes them from the earlier single-receptor agent almorexant and from the GABAergic mechanism of zolpidem or eszopiclone.

Why Mechanism Matters Clinically

Because DORAs do not produce broad CNS depression, they carry a lower theoretical risk of respiratory suppression, complex sleep behaviors, and rebound insomnia compared with benzodiazepines. The FDA still classifies both agents as Schedule IV controlled substances, and prescribers should screen for obstructive sleep apnea before initiating either drug. 3

Suvorexant (Belsomra): The Key Trial Evidence

Suvorexant received FDA approval in August 2014, making it the first DORA to reach the U.S. Market. The registration program included a large phase 3 trial published in Lancet Neurology.

Herring et al. 2014: Key Numbers

Herring WJ et al. (Lancet Neurol 2014, N=1,021 combined across two parallel studies) randomized adult and elderly insomnia patients to suvorexant 20 mg/40 mg (adults), 15 mg/30 mg (elderly), or placebo for three months. 1 At month 1, the 40 mg adult dose reduced subjective sleep-onset latency (sSOL) by roughly 22 minutes from baseline compared with about 11 minutes for placebo. Wake after sleep onset (WASO) fell by approximately 28 minutes on suvorexant 40 mg versus 15 minutes on placebo at month 3, a statistically significant difference (P<0.001).

The 20 mg dose, which is now the FDA-approved maximum for adults, also outperformed placebo on both endpoints, though effect sizes were smaller. That dose distinction matters because the FDA rejected the 40 mg dose over next-morning residual sedation concerns, limiting the commercially available ceiling to 20 mg. 3

Sleep Architecture Under Suvorexant

Polysomnographic data from the Herring trial showed suvorexant preserved or modestly increased REM sleep, a pattern consistent with orexin blockade rather than GABAergic sedation. 1 Slow-wave sleep proportions were not significantly reduced. This sleep-architecture profile is one reason DORAs are often preferred over benzodiazepines in older adults, where suppression of slow-wave sleep has particular consequences for cognitive consolidation.

Adverse Effects Specific to Suvorexant

In the Herring trial, somnolence was the most common adverse event, reported by 7% on suvorexant 20 mg versus 3% on placebo. 1 Next-morning driving impairment was assessed in a separate FDA-requested study; the 20 mg dose produced measurable impairment on a driving simulator at 9 hours post-dose in some participants, which influenced the label wording. 4

Lemborexant (Dayvigo): The SUNRISE Program Evidence

Lemborexant was approved by the FDA in December 2019. The SUNRISE clinical program included two key trials. SUNRISE-1 is the most directly relevant to an efficacy comparison because it included an active comparator arm.

SUNRISE-1: Design and Primary Results

SUNRISE-1 (N=1,006, published JAMA Netw Open 2019) randomized adults aged 55 years and older with insomnia disorder to lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, or placebo for 30 days. 2 The primary endpoint was sleep efficiency (SE) measured by polysomnography at month 1.

Both lemborexant doses significantly outperformed placebo on SE. Lemborexant 10 mg produced a mean SE of 79.0% compared with 74.2% for zolpidem ER 6.25 mg and 71.5% for placebo. 2 Lemborexant 5 mg achieved 77.4% SE. The difference between lemborexant 10 mg and zolpidem ER was statistically significant (P<0.05).

SUNRISE-1: Wake After Sleep Onset

WASO outcomes further differentiated lemborexant from the active comparator. Lemborexant 10 mg reduced WASO by 27.0 minutes from baseline at month 1 versus a 20.0-minute reduction for zolpidem ER 6.25 mg (P<0.05). 2 Sleep onset latency on polysomnography (LPS) also favored both lemborexant doses over placebo, with the 10 mg dose reducing LPS by approximately 10 minutes more than placebo.

SUNRISE-2: Long-Term Data

SUNRISE-2 (N=949, 12-month study) confirmed that lemborexant 5 mg and 10 mg maintained efficacy on subjective sleep measures across 12 months without clinically meaningful tolerance development. 5 Rebound insomnia on discontinuation was not significantly different from placebo, a finding that supports the class's favorable discontinuation profile relative to benzodiazepines.

Driving and Next-Morning Function

A key differentiator in the lemborexant data package is the FDA-requested next-morning driving simulation study. Lemborexant 10 mg did not produce statistically significant driving impairment at 9 hours post-dose compared with placebo, whereas zolpidem ER 6.25 mg did show significant impairment. 6 This study enrolled 60 healthy adults aged 55 and older and used the standard deviation of lateral position (SDLP) as the primary measure of driving performance.

No Direct Head-to-Head RCT Exists

This is the single most important caveat for every comparison article on this topic. No published randomized controlled trial has enrolled patients and randomized them to suvorexant versus lemborexant in the same study. Every efficacy comparison must therefore rely on indirect cross-trial inference, which carries significant limitations including differences in patient populations, polysomnography protocols, study duration, and baseline insomnia severity. 7

The framework below outlines how a clinician can approach this comparison using available trial data, given the absence of a direct RCT.

Cross-Trial Indirect Comparison: Key Caveats

| Efficacy Domain | Suvorexant 20 mg (Herring 2014) | Lemborexant 10 mg (SUNRISE-1) | Comparability | |---|---|---|---| | Subjective SOL reduction vs placebo | ~11 min | ~10 min (LPS, PSG) | Low (different metrics) | | WASO reduction vs placebo | ~13 min (month 3) | ~27 min (month 1) | Low (different timepoints) | | Sleep efficiency vs placebo | Not primary endpoint | +7.5 percentage points | Cannot compare | | Next-morning driving | Impairment at 9h (20 mg) | No significant impairment at 9h (10 mg) | Moderate (similar protocols) | | Active comparator | Placebo only | Zolpidem ER 6.25 mg | Different trial designs |

The WASO gap in this table looks large, but it almost certainly reflects the different assessment timepoints (month 1 for SUNRISE-1, month 3 for Herring) rather than a true 2x efficacy advantage for lemborexant. A prescriber should not conclude lemborexant is twice as effective at reducing nighttime waking based on this comparison alone.

Dosing Comparison and Titration

Getting the dose right affects both efficacy and tolerability for both agents.

Suvorexant Dosing

Suvorexant is initiated at 10 mg taken no more than 30 minutes before bedtime, with at least 7 hours remaining before the planned wake time. 3 The dose may be increased to 20 mg if 10 mg is tolerated but insufficiently effective. The 20 mg dose is the approved maximum; the FDA rejected 40 mg over residual sedation concerns identified in Herring 2014. No dose adjustment is required for mild or moderate hepatic impairment, but suvorexant is not recommended in severe hepatic impairment. 3

Lemborexant Dosing

Lemborexant is initiated at 5 mg, taken immediately before bed with at least 7 hours remaining. 8 The dose may be increased to 10 mg if clinically needed. For patients taking moderate CYP3A inhibitors, the maximum recommended dose is 5 mg. Lemborexant is contraindicated with strong CYP3A inhibitors. 8 This metabolic distinction is clinically relevant for patients on azole antifungals or certain HIV antiretrovirals.

Elderly Patients

Both agents have specific considerations in older adults. The SUNRISE-1 trial exclusively enrolled patients aged 55 and older, providing the most strong dataset for lemborexant in this population. 2 For suvorexant, the Herring 2014 elderly subgroup used a 15 mg/30 mg dose range; the currently approved maximum for all adults including the elderly remains 20 mg. A 2021 review in the Journal of the American Geriatrics Society recommended DORAs as preferred first-line agents over benzodiazepines for older adults with chronic insomnia. 9

Safety Profiles Side by Side

Shared Class Risks

Both drugs carry an FDA-required warning for complex sleep behaviors (sleep-walking, sleep-driving) and should be stopped immediately if these occur. 3 8 Worsening of depression and emergence of suicidal ideation are also class-level warnings shared with other insomnia pharmacotherapies.

Somnolence Rates

Somnolence was reported in 7% of suvorexant 20 mg users versus 3% placebo in Herring 2014. 1 In SUNRISE-1, somnolence occurred in 10% of lemborexant 10 mg users versus 1% placebo. 2 These percentages come from different trials with different populations, so direct comparison is again unreliable. Numerically, the somnolence rate looks slightly higher for lemborexant 10 mg, which is consistent with its higher pharmacological potency at the receptor level.

Respiratory Cautions

Suvorexant carries a specific precaution for use in patients with compromised respiratory function, including sleep apnea. 3 Lemborexant labeling includes similar language. A 2020 study in SLEEP (N=25 patients with mild-to-moderate obstructive sleep apnea) found that suvorexant 20 mg did not significantly worsen the apnea-hypopnea index compared with placebo, but the sample size was small. 10

Drug Interactions

Lemborexant is primarily metabolized by CYP3A4, creating meaningful drug interactions. 8 Suvorexant is also metabolized mainly by CYP3A, with similar interaction potential. For a patient on moderate CYP3A inhibitors such as fluconazole or diltiazem, lemborexant's 5 mg maximum dose cap provides a concrete clinical decision point. 8 Suvorexant's label recommends starting at 5 mg rather than 10 mg in this scenario. 3

Guideline Positioning of Both Drugs

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for Chronic Insomnia recommended suvorexant as a standard therapy for sleep-maintenance insomnia, citing a net benefit versus the risk profile. 11 The guideline did not cover lemborexant because it predates the 2019 FDA approval.

A 2022 update from the AASM published in the Journal of Clinical Sleep Medicine recommended both DORAs as treatment options for chronic insomnia disorder, stating: "Clinicians should use suvorexant or lemborexant for sleep onset and sleep maintenance insomnia in adults." 12 The same guideline gave a conditional recommendation in favor of lemborexant over suvorexant when next-morning function is a high clinical priority, based on the comparative driving simulation data.

The American College of Physicians (ACP) 2016 guideline on insomnia management recommended cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment before any pharmacotherapy. 13 Neither DORA changes that priority. CBT-I should be offered first or concurrently with pharmacotherapy for chronic insomnia.

Cost, Generic Availability, and Access

Suvorexant lost patent exclusivity in 2023. Generic suvorexant became available in the United States by mid-2023, and cash prices at major pharmacies dropped substantially, with GoodRx listing prices around $50 to $80 per 30-day supply for the 20 mg generic as of early 2025. Lemborexant remains brand-only (Dayvigo) as of July 2025, with cash prices typically exceeding $400 per month without insurance. 14

For patients without strong clinical reasons to prefer lemborexant specifically, generic suvorexant now offers a substantially lower-cost option in the same drug class.

Who Should Take Which Drug: A Clinical Decision Guide

The absence of a direct head-to-head RCT means prescribers must use indirect evidence and patient-specific factors to choose between these agents.

Prefer Lemborexant When

The patient is aged 55 or older, has safety concerns about next-morning sedation (e.g., drives early, operates machinery), or has failed suvorexant at 20 mg without adequate sleep-maintenance benefit. The SUNRISE-1 driving data and the AASM 2022 conditional recommendation both support this choice. 12 Start at 5 mg and assess after 1 to 2 weeks.

Prefer Suvorexant When

Cost is a significant barrier and generic access is available. The patient has a known CYP3A inhibitor in their regimen that would cap lemborexant at 5 mg anyway. Evidence from a long-term open-label extension of the Herring program showed continued efficacy through 12 months without tolerance development. 15

Both Are Reasonable When

The patient has no specific features that differentiate one from the other, CBT-I has been offered or completed, and the clinical goal is primarily sleep-onset difficulty without next-morning function concerns.

Can You Switch from Belsomra to Dayvigo?

Switching is straightforward because both agents share the same mechanism and receptor targets. No washout period is required between them; a patient can take the last suvorexant dose one night and start lemborexant the next. 3 8

Start lemborexant at 5 mg regardless of the suvorexant dose the patient was using. Titrate to 10 mg after 1 to 2 weeks if the 5 mg dose is tolerated but not sufficiently effective. Patients should be counseled that both drugs need at least 7 hours of sleep opportunity, and that the transition may come with a brief re-stabilization period of 3 to 7 days as the body adjusts to the slightly different receptor-binding kinetics.